SMMT Summit Therapeutics Inc.
$17.55▲ +3.24%
Healthcare
Other
After hours
$17.70▲ +0.85%
Sep 11, 7:58 PM ET
Volume 4.27M
Avg Volume (10D) 6.09M
Key Metrics & Fundamentals
Market Cap
$14.00B
P/E Ratio
–
Div Yield
–%
52W Range
12.07 - 29.23
% vs 50 MA
21.38%
% vs 200 MA
6.83%
RSI-14
67.0
MACD Histogram
+0.4200
Beta (1Y vs SPY)
1.77
Free Cash Flow
-$142.03M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$224.75M
COGS
–
Operating Exp
$220.50M
Operating Income
-$220.50M
EBIT
-$220.50M
Pretax Income
-$215.70M
Net Income
-$215.70M
EPS (Diluted)
-0.28
Price & Volume History
Loading chart…
Recent News
Summit Therapeutics Shares Rise After Upgrade From Jefferies
MT Newswires · Sep 9, 2026 7:00 PM
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy
InvestorsHub · Sep 9, 2026 2:07 PM
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls
The Fly · Sep 9, 2026 1:51 PM
Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15
MT Newswires · Sep 9, 2026 11:42 AM
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
Insider Monkey · Sep 9, 2026 1:32 AM
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
Insider Monkey · Sep 7, 2026 5:53 AM
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Zacks · Sep 4, 2026 2:37 PM
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Investor's Business Daily · Sep 3, 2026 8:51 PM
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Barrons.com · Sep 3, 2026 4:00 PM
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Business Wire · Sep 2, 2026 9:41 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SMMT's money flow as a full page
Social Sentiment
Avg +0.36 · 19 posts
DiscussionBioNTech ($BNTX) is arguably the most undervalued stock in the biotech sector today and i dont understand why
r/stocks · Jul 6, 2026
positive
+0.40
NewsDiscussionDDVery confused by $SMMT
r/stocks · Jun 1, 2026
Despite promising trial data, the post expresses confusion and highlights negative aspects (earnings, ASCO speaker criticism), indicating a bearish sentiment towards the stock.
negative
-0.40
NewsTradeDiscussionPHARMA Insider trades (SMMT)
r/wallstreetbets · Oct 24, 2025
Insider trading activity, especially with large accumulation of shares, is generally viewed as a positive signal of confidence in the company's future, though potentially raises red flags for some investors.
positive
+0.60
DDDiscussionSMMT YOLO - Trial Data Results 9/7/2025. Concentration creates or destroys wealth. Let’s get it nerds
r/wallstreetbets · Aug 28, 2025
The comments about co-CEOs buying stock and a long-term hold suggest optimism regarding SMMT's future.
positive
+0.60
NewsDiscussionTrade(04/28) Interesting Stocks Today
r/StockMarket · Apr 28, 2025
Discussion about a potential supply chain shock related to Trump's tariffs, with reference to NIO and Nvidia.
positive
+0.60
Page 1 of 4 (19 total)
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.